Nurse practitioners top the list of hires as facility operators attempt to reduce care disruption and increase timely response to staff members’ medical questions, investigators say.
Trials to Test Vaccine Mixing With Booster Doses By Ralph Ellis
July 1, 2021 Clinical trials are being conducted across the United States to see if giving fully vaccinated adults a different kind of booster dose is effective.
One of the participating sites is the University of Pittsburgh School of Medicine, which is now recruiting volunteers.
“As more and more COVID-19 variants are identified, we need to figure out how we, as a community, can stay protected,” Judy Martin, MS, a professor of pediatrics at the Pitt Medical School and a member of Pitt’s Center for Vaccine Research, said in a news release.
Study shows how mutant protein clusters drive disease-causing aggregates
A mutation that replaces a single amino acid in a potent tumor-suppressing protein turns it from saint to sinister. A new study by a coalition of Texas institutions shows why that is more damaging than previously known.
The ubiquitous p53 protein in its natural state, sometimes called “the guardian of the genome,” is a front-line protector against cancer. But the mutant form appears in 50% or more of human cancers and actively blocks cancer suppressors.
Researchers led by Peter Vekilov at the University of Houston (UH) and Anatoly Kolomeisky at Rice University have discovered the same mutant protein can aggregate into clusters. These in turn nucleate the formation of amyloid fibrils, a prime suspect in cancers as well as neurological diseases like Alzheimer’s.
E-Mail
IMAGE: A model produced by scientists at Rice University shows the conformational changes caused by a mutation in the cancer-fighting p53 protein. At top left, the red box highlights the aggregation-prone. view more
Credit: Kolomeisky Research Group/Rice University
HOUSTON - (March 4, 2021) - A mutation that replaces a single amino acid in a potent tumor-suppressing protein turns it from saint to sinister. A new study by a coalition of Texas institutions shows why that is more damaging than previously known.
The ubiquitous p53 protein in its natural state, sometimes called the guardian of the genome, is a front-line protector against cancer. But the mutant form appears in 50% or more of human cancers and actively blocks cancer suppressors.
GALVESTON Even after much of the general population gets COVID-19 vaccines, they will likely need to get annual doses to protect against future mutations of the virus, according to researchers at the University of Texas Medical Branch at Galveston. Scott Weaver, director of the medical branch’s infectious disease research programs, said viruses like COVID-19 will eventually find ways to mutate in order to continue to infect people, even those.